Capricor to Present Positive Five-Year HOPE-2 OLE Data and HOPE-3 Phase 3 Results for Deramiocel in Duchenne Muscular Dystrophy at PPMD 2026 Annual Conference

Capricor Therapeutics (CAPR) announced positive five-year efficacy and safety data for deramiocel in Duchenne muscular dystrophy, a rare, severe genetic disorder. The HOPE-2 Open-Label Extension study demonstrated durable skeletal and cardiac muscle benefits with a meaningful slowdown in disease progression: pulmonary function decline (PUL) attenuated to approximately 1 percentage point year-over-year, substantially better than the natural disease course. This durability signal is critical for rare disease therapeutics seeking regulatory approval.

The data reinforces momentum from the previously reported HOPE-3 Phase 3 results, which met both primary and key secondary endpoints with statistical significance. No new safety signals emerged across either study, establishing a favorable risk-benefit profile essential for rare indication development. Presentation at PPMD 2026 Annual Conference in high-visibility sessions (late-breaking and cardiac care tracks) signals clinical credibility within the muscular dystrophy community.

For CAPR, positive Phase 3 and long-term extension data represent a de-risking event approaching potential regulatory decision points. Cell and exosome-based therapeutics remain experimental, but five-year durability in a progressive neuromuscular disease addresses a key unmet need. Investor focus will shift toward FDA/EMA feedback timelines and commercial readiness for a ultra-rare indication with limited but loyal patient population.

Sector implication: Success in rare genetic diseases elevates the entire biotechnology subsector's risk-adjusted return profile. Positive Phase 3 data in high-unmet-need indications typically correlate with equity re-rating and increased institutional capital rotation into specialized biotech platforms.